Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer


-    Experienced biopharma professional focused on drug product development 

Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today announced the appointment of Dr. Sabine Hauck as Chief Technology Officer (CTO). 

Dr. Sabine Hauck is a highly experienced biopharmaceutical professional. She has been working in the field of drug product development in biopharma and specialty pharma for more than 20 years. Notably, she brings more than a decade of experience with liposomal products. Her expertise covers process development, chemistry, manufacturing and controls as well as bioanalytics, quality management and regulatory affairs. Sabine joins Thermosome from Leukocare AG, where she was Executive Vice President Corporate Development. During her professional career, which has included roles at Medigene AG and IDEA AG, Sabine was actively involved in bringing liposomal drug candidates into clinical Phase III studies and registration. She was also responsible for regulatory affairs and international registration procedures. She succeeds Thermosome's former Chief Operating Officer, Dr. Uwe Michaelis.